Mounjaro improves how your body responds to insulin, helping to address this underlying problem
Some of these approaches, despite not currently being listed in the summary of product characteristics, can effectively mitigate the occurrence and severity of adverse effects, notably enhancing patients adherence to treatment and persistence
20 In agreement with the ADA, the American Association of Clinical Endocrinologists (AACE) lists DPP-4 inhibitors as an alternative in patients with an A1C under 7.5% in whom the use of metformin is contraindicated
They are a metabolic tool and like any tool, their outcome depends entirely on how you use them
Weight loss may slow slightly from the pace of months 2 through 4, but total results are compounding
Our priority is always patient safety and transparencyif you are interested in peptide therapies or pain management options, we invite you to schedule a consultation to discuss what is safe, effective, and available for your individual needs